Repros to Present Androxal(R) and Proellex(R) Clinical Updates at the Lazard Capital Markets 9th Annual Healthcare Conference

        Print
| Source: Repros Therapeutics Inc.

THE WOODLANDS, Texas, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today announced the Company will present clinical updates for both its Androxal® and Proellex® programs Wednesday, November 14, 2012, at 8 am Eastern time. The Company is not webcasting the presentation but will have the slides available on its website, www.reprosrx.com, the morning of the presentation.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund development of its Androxal® and Proellex® programs, have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com.

The Repros Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7738

Repros Therapeutics Inc.
Joseph Podolski (281) 719-3447
President and Chief Executive Officer

Investor Relations:
Thomas Hoffmann
The Trout Group
(646) 378-2931